Recent News

• 06.01.2026 - Definium Therapeutics Announces New Employee Inducement Grants
• 05.21.2026 - Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
• 05.12.2026 - Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
• 05.11.2026 - Definium Therapeutics Announces New Employee Inducement Grants
• 05.07.2026 - Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
• 04.30.2026 - Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
• 04.22.2026 - Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day
• 04.20.2026 - Definium Therapeutics Announces New Employee Inducement Grants

Recent Filings

• 05.19.2026 - EX-99.1 EX-99.1
• 05.19.2026 - 8-K Current report
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.12.2026 - EX-99.1 EX-99.1
• 05.12.2026 - 8-K Current report
• 05.07.2026 - 8-K Current report
• 05.07.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.07.2026 - EX-99.1 EX-99.1
• 04.27.2026 - DEF 14A Other definitive proxy statements
• 04.27.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material